Patents by Inventor Richard T. Cummings

Richard T. Cummings has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Reagents for assaying Bacillus anthracis lethal factor protease
    Patent number: 6955891
    Abstract: The present invention features a Bacillus anthracis lethal factor substrate. The substrate can be used for example to measure lethal factor activity. Preferred substrates contain one or mare detectable labels and have a sufficiently high turnover rate for applications in a high throughput screen.
    Type: Grant
    Filed: April 28, 2003
    Date of Patent: October 18, 2005
    Assignee: Merck & Co., Inc.
    Inventors: Barry R. Cunningham, Richard T. Cummings, Jeffrey D. Hermes, Scott Salowe
  • Benzimisazo[4,5-f]isoquinolinone derivatives
    Patent number: 6852727
    Abstract: Benzimidazo[4,5-f]isoquinolinone derivatives are inhibitors of Janus protein tyrosine kinases (Jak), and as such are useful as immunosuppressants, and in the treatment of diseases including asthma, allergies, autoimmune diseases.
    Type: Grant
    Filed: July 26, 2002
    Date of Patent: February 8, 2005
    Assignee: Merck & Co., Inc.
    Inventors: Joung L. Goulet, Rose M. Cubbon, Richard T. Cummings, Xingfang Hong, Peter J. Sinclair, James E. Thompson
  • Benzimisazo[4,5-f]isoquinolinone derivatives
    Publication number: 20040176601
    Abstract: Benzimidazo[4,5-f]isoquinolinone derivatives are inhibitors of Janus protein tyrosine kinases (Jak), and as such are useful as immunosuppressants, and in the treatment of diseases including asthma, allergies, autoimmune diseases.
    Type: Application
    Filed: January 30, 2004
    Publication date: September 9, 2004
    Inventors: Joung L. Goulet, Rose M Cubbon, Richard T Cummings, Xingfang Hong, Peter J Sinclair, James E Thompson
  • Assays for nuclear receptor agonists and antagonists using fluorescence resonance energy transfer
    Patent number: 6689574
    Abstract: Provided is a method of identifying agonists and antagonists of nuclear receptors that comprises measuring agonist-dependent fluorescence resonance energy transfer (FRET) between a fluorescently labeled nuclear receptor or ligand binding domain and fluorescently labeled CREB-binding protein (CBP), p300, other nuclear co-activator, or binding portion thereof. The method is simple, rapid, and inexpensive. Nuclear receptors and nuclear receptor co-activators labeled with fluorescent reagents for use in the above-described method are also provided.
    Type: Grant
    Filed: October 5, 1998
    Date of Patent: February 10, 2004
    Assignee: Merck & Co., Inc.
    Inventors: Richard T. Cummings, David E. Moller, Jeffrey D. Hermes, Gaochao Zhou
  • Reagents and methods for assaying Bacillus anthracis lethal factor protease
    Publication number: 20040019182
    Abstract: The present invention features a Bacillus anthracis lethal factor substrate and assays employing the substrate to measure lethal factor activity and to screen for compounds affecting lethal factor activity. Preferred substrates contain one or more detectable labels and have a sufficiently high turnover rate to be suitable for use in a high throughput screen.
    Type: Application
    Filed: April 28, 2003
    Publication date: January 29, 2004
    Inventors: Barry R. Cunningham, Richard T. Cummings, Jeffrey D. Hermes, Scott Salowe